Cerebrum 40: Study on maintaining cognitive performance through advanced neuroregulation Randomized, controlled and multicenter clinical trial

Age-associated neurocognitive decline often begins subclinically, between the ages of 40 and 50, accelerated by occupational stress, lack of self-regulation, and adaptive exhaustion. The Cerebrum 40 study investigated the impact of a multimodal neurotechnology intervention – Neurofeedback Plus – on cognitive performance, physiological resilience, and subjective perception of mental functioning among active adults. The study was randomized, controlled, longitudinal, conducted on a sample of 400 participants (200 experimental, 200 control), with a duration of 12 months. The intervention integrated personalized EEG neurofeedback, brain photobiomodulation, HRV biofeedback, and transcutaneous vagal stimulation, applied in 3 therapeutic cycles. The evaluation was performed through qEEG, HRV, biofeedback and validated questionnaires. Statistical analyses included t-tests, ANOVA, multiple regression, PCA, and correlations between objective markers and perceptions. The intervention produced significant reductions in perceived burnout (t = +6.28, p < .00001), increases in vagal tone (RMSSD, t = -13.37, p < .00001), and an improvement in EEG coherence in executive (BA8), semantic (BA44/45), and attentional (BA7) networks. ANOVA 2x2 confirmed the existence of a statistically significant interaction effect, Group x Time, for RMSSD (F= 91.23, p < .00001). Regression analysis showed that BA44/45 (coef. = +14.52, p = .038) and RMSSD (coef. = –0.14, p = .001) independently predict the level of burnout. PCA identified 3 latent functional dimensions: vagal regulation, executive coherence, and semantic stress. The Cerebrum 40 study scientifically validates Neurofeedback Plus as a standardized, effective, and safe intervention for the prevention of early cognitive decline. The results support the integration of the protocol into longevity medicine and public health strategies for the adult active population, providing a new clinical model of neurophysiological and psychological support through advanced, non-pharmacological technologies.